Tim Hunt, JD, CEO of the ARM
Tim Hunt, JD, CEO of the Alliance for Regenerative Medicine (ARM)

Recent discussions among biotech CEOs in the cell and gene therapy sector, convened at a conference in Carlsbad, California, have illuminated survival strategies in the face of industry challenges. The leaders disclosed their pragmatic approaches to conserve limited cash, opting for smaller, agile teams focused on a select number of projects. Responding to the industry’s slowdown, CEOs underscored the importance of partnering with external firms possessing specialized manufacturing and research expertise. Acknowledging that these adjustments are driven by financial constraints, they emphasized the positive impact of increased efficiency for biotech companies in any market.1

Concurrently, the conference delved into ethical challenges within cell and gene therapy, particularly addressing the expensive pricing and economic sustainability of these treatments. Durhane Wong-Rieger, CEO of the Canadian Organization for Rare Diseases, emphasized the ethical dilemma of groundbreaking therapies being inaccessible to those in dire need. Tay Salimullah from Novartis Gene Therapies questioned the ethics of expensive therapies, noting the potential exclusion of patients from life-saving treatments. Janet Lambert proposed global democratization through public-private partnerships, recognizing challenges in commercializing advanced therapies.2

J. Benjamin Hurlbut voiced concerns about the pricing and economic sustainability of gene and cell therapy, stressing the crucial role of ethical considerations in determining their societal value. The speakers collectively acknowledged the responsibility of the entire community—drug makers, regulators, insurance companies, and health systems—in ensuring ethical practices. They underscored the need to avoid failures of responsibility, foster compassion, and recognize the profound implications of expensive pricing in this transformative field.2

Amid the industry’s financial stringency and the persistent challenge of making therapies accessible, PackGene remains steadfast in its commitment to making gene therapy affordable. Our dedicated team consistently enhances the π-Alpha 293 AAV High-yield Platform, striving to reduce manufacturing costs and improve the accessibility of gene therapy. For more information about our services and technology platforms, visit https://www.packgene.com, as we continue to support the gene and cell therapy industry in ultimately helping more patients.

Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.


AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.


aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.